Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study. Salmerón Ríos S, et al, J Am Geriatr Soc 2021.
Notes sur les tags :
Réaliser des modifications :
Pour modifier ce document, il est nécessaire d'être connecté au site. Pour cela, assurez-vous d'avoir des identifiants valides. Si vous n'en avez pas,
contactez-nous. Pour vous connecter, cliquez sur l'icône
dans la barre de navigation.
Résumé et points clés
Background/objectives: The safety and immunogenicity of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in older adults with different frailty and disability profiles have not been well determined. Our objective was to analyze immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older adults across frailty and disability profiles.
Design: Multicenter longitudinal cohort study.
Setting and participants: A total of 134 residents aged ≥65 years with different frailty and disability profiles in five long-term care facilities (LTCFs) in Albacete, Spain. INTERVENTION AND
Measurements: Residents were administered two vaccine doses as per the label, and antibody levels were determined 21.9 days (SD 9.3) after both the first and second dose. Functional variables were assessed using activities of daily living (Barthel Index), and frailty status was determined with the FRAIL instrument. Cognitive status and comorbidity were also evaluated.
Results: Mean age was 82.9 years (range 65-99), and 71.6% were female. The mean antibody titers in residents with and without previous COVID-19 infection were 49,878 AU/ml and 15,274 AU/ml, respectively (mean difference 34,604; 95% confidence interval [CI]: 27,699-41,509). No severe adverse reactions were observed, after either vaccine dose. Those with prevaccination COVID-19 had an increased antibody level after the vaccine (B = 31,337; 95% CI: 22,725-39,950; p < 0.001). Frailty, disability, older age, sex, cognitive impairment, or comorbidities were not associated with different antibody titers.
Conclusions: The BNT162b2 mRNA COVID-19 vaccine in older adults is safe and produces immunogenicity, independently of the frailty and disability profiles. Older adults in LTCFs should receive a COVID-19 vaccine.
Références de l'article
- Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.
- Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.
- Salmerón Ríos S, Mas Romero M, Cortés Zamora EB, Tabernero Sahuquillo MT, Romero Rizos L, Sánchez-Jurado PM, Sánchez-Nievas G, Señalada JJB, García Nogueras I, Estrella Cazalla JdD, Andrés-Pretel F, Murillo Romero A, Lauschke VM, Stebbing J, Abizanda P
- Journal of the American Geriatrics Society
- 2021
- J Am Geriatr Soc. 2021 Jun;69(6):1441-1447. doi: 10.1111/jgs.17153. Epub 2021 Apr 2.
- Activities of Daily Living, Aged, Aged, 80 and over, *Antibody Formation, BNT162 Vaccine, COVID-19/*prevention & control, COVID-19 Serological Testing, COVID-19 Vaccines/*immunology/*therapeutic use, Comorbidity, *Disabled Persons, Female, *Frail Elderly, Health Status Indicators, Humans, Longitudinal Studies, Male, Nursing Homes, SARS-CoV-2, Spain
- COVID19, Vaccination, Fragilité, Efficacité, Pfizer
- Liens
- Traduction automatique en Français sur Google Translate
- DOI: 10.1111/jgs.17153
- PMID: 33768521
- Articles similaires
- Cité par
- Références
- Texte complet gratuit
- Twitter
- Twitter cet article (lien vers l'article)
- Twitter cet article (lien vers cette page)
Éditer la discussion
Références